SEC Form 4 · accession 0001104659-15-021403
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Officer — Chief Operating Officer
Period of report
Mar 19, 2015
Accepted (ET)
Mar 20, 2015 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 19, 2015 | M | 27,105 | $4.09 | A | 139,426 | D | |
| Common StockF1,F2 | Mar 19, 2015 | S | 17,307 | $16.43 | D | 122,119 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $4.09 | Mar 19, 2015 | M | 27,105 | D | — | Apr 1, 2015 | Common Stock | 27,105 | 0 | D |
Explanation of responses
- F1In connection with the exercise of expiring stock options, 17,307 shares were sold to satisfy the exercise price and the reporting person's tax withholding obligations.
- F2Reflects the weighted average sale price. The range of prices for such transaction is $16.25 to $16.58. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The options vested in full on April 10, 2010.